A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 mg/m(2) intravenously twice weekly for 3 of 4 we...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Siegel, David S., Martin, Thomas, Wang, Michael, Vij, Ravi, Jakubowiak, Andrzej J., Lonial, Sagar, Trudel, Suzanne, Kukreti, Vishal, Bahlis, Nizar, Alsina, Melissa, Chanan-Khan, Asher, Buadi, Francis, Reu, Frederic J., Somlo, George, Zonder, Jeffrey, Song, Kevin, Stewart, A. Keith, Stadtmauer, Edward, Kunkel, Lori, Wear, Sandra, Wong, Alvin F., Orlowski, Robert Z., Jagannath, Sundar
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2012
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123387/
https://ncbi.nlm.nih.gov/pubmed/22833546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-425934
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia